News | April 27, 2023
Biocon approves NCD issue
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Apollo continues to invest in genomics technology and research for better patient care
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Subscribe To Our Newsletter & Stay Updated
